Dexcom Inc. (NASDAQ: DXCM) is currently under scrutiny from several securities‑fraud class‑action lawsuits. The lawsuits were filed by law firms Kessler Topaz Meltzer & Check LLP and Bernstein Liebhard LLP, as well as Levi & Korsinsky LLP, on behalf of investors who purchased or otherwise acquired Dexcom securities between 2019 and 2025. The filings allege that Dexcom misrepresented its financial condition and product performance, thereby inducing investors to buy its stock at inflated prices. The plaintiffs claim that these alleged misstatements caused them to suffer losses when the stock subsequently fell.

In response, the plaintiffs’ attorneys have issued investor alerts and deadline reminders. Kessler Topaz Meltzer & Check LLP has warned investors that the deadline to join the lawsuit is approaching, urging them to contact the firm before the cutoff date. Similarly, Levi & Korsinsky LLP has requested that investors join the action by December 26, 2025, to secure the possibility of a recovery. Bernstein Liebhard LLP has announced that a class action has been filed and is seeking to bring additional investors into the group.

Despite the legal turmoil, some analysts remain optimistic about Dexcom’s long‑term prospects. Mizuho Financial Group has raised its price target for Dexcom from $75.00 to $78.00 and maintains an “outperform” rating for the company. The firm’s updated target reflects an expectation of strong price appreciation, presumably based on Dexcom’s continued development of continuous glucose monitoring technology and its expanding product portfolio.

However, the company’s stock has experienced modest guidance‑related declines in recent weeks. An article on InsiderMonkey reported that Dexcom’s shares fell after the company issued guidance that fell short of analyst expectations. The drop was attributed to market concerns about the company’s revenue trajectory and potential headwinds from competition in the diabetes management market.

Investors who have suffered losses from recent price declines have been advised to contact the Gross Law Firm to discuss the possibility of joining the ongoing class action. The firm has been active in advising clients on how to proceed with potential claims against Dexcom.

Dexcom’s market capitalization stands at approximately $25.6 billion, with a current share price of $65.91 as of December 17, 2025. The company’s price‑earnings ratio is 36.71, indicating that investors are pricing in significant growth expectations. Dexcom’s 52‑week high was $93.25 in February 2025, while the 52‑week low was $54.11 in November 2025. The company’s financials and product pipeline remain key focal points for both analysts and investors navigating the current legal and market environment.